Allergan trims fat to halt takeover

Share this article:

Allergan is trimming the fat as part of efforts to head off a possible takeover by Valeant, two sources confirmed to Bloomberg. The company's restructuring plan is thought to include company-wide cost cuts, including some “legacy expenses,” the news service reported.

Allergan has rebuffed Valeant's last three offers since April, saying the offers do not reflect Allergan's value. Allergan CEO David Pyott set a five-year plan for cost-cutting targets in motion after the company rejected Valeant's initial bid.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters